Our results revealed pathways that are known to be therapeutically important and new putative drug targets, including CD40 in rheumatoid arthritis, lymphotoxin-α (LTA) in multiple sclerosis and the chemokine CXCL5 in UC. This evidence concerns the gene CD40 and rheumatoid arthritis.